Go Girls! Fitness Support Group Intervention Effectiveness Study (CBS002)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Christine Burt Solorzano, MD
- Phone Number: 434-924-9084
- Email: cmb6w@virginia.edu
Study Contact Backup
- Name: Melissa Gilrain
- Phone Number: 434-243-6911
- Email: pcos@virginia.edu
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Recruiting
- Center for Research in Reproduction, University of Virginia
-
Contact:
- Christine M Burt Solorzano, MD
- Phone Number: 434-924-9084
- Email: pcos@virginia.edu
-
Principal Investigator:
- Christine M Burt Solorzano, MD
-
Contact:
- Melissa Gilrain
- Phone Number: 434-243-6911
- Email: pcos@virginia.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female
- Ages 10-18 yr
- Participating in the Go Girls! program
- With diagnoses of abnormal weight gain, excess weight, insulin resistance, PCOS, premature adrenarche, or type 2 diabetes mellitus
Exclusion Criteria:
- Known pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Go Girls! Fitness Support Group
|
Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls.
The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in mean score for the PACES scale after 6-months of intervention
Time Frame: Baseline and 6 months
|
Enjoyment of exercise will be assessed by scores on the PACES modified for adolescent girls, which is scored on a scale of 1 to 5.
|
Baseline and 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in mean score for the PACES scale after 3-months of intervention
Time Frame: Baseline and 3 months
|
Enjoyment of exercise will be assessed by scores on the PACES modified for adolescent girls, which is scored on a scale of 1 to 5.
|
Baseline and 3 months
|
|
Change in amounts of average daily moderate-vigorous exercise
Time Frame: Baseline, 3 months, and 6 months
|
Amounts of average daily moderate-vigorous exercise will be assessed by recall of previous week's exercise amounts spent doing moderate-vigorous physical activity.
|
Baseline, 3 months, and 6 months
|
|
Change in amounts of average daily vigorous exercise
Time Frame: Baseline, 3 months, and 6 months
|
Amounts of average daily vigorous exercise will be assessed by recall of previous week's exercise amounts spent doing vigorous physical activity
|
Baseline, 3 months, and 6 months
|
|
Changes in attitudes about exercise
Time Frame: Baseline, 3 months, 6 months
|
Responses will be compiled into descriptive summaries/themes of girls' attitudes before, during, and after the intervention
|
Baseline, 3 months, 6 months
|
|
Changes in anthropometric and biochemical indices of metabolism and possible PCOS
Time Frame: Baseline, 3 months, 6 months
|
We will be assessing changes in blood pressure, body mass index total and percentile-for-age, waist circumference, serum markers of androgen excess and/or PCOS (free testosterone calculated from total testosterone and sex hormone binding globulin, dehydroepiandrosterone sulfate, and luteinizing hormone: follicle stimulation hormone ratio), serum markers of insulin resistance (insulin, glucose, HbA1c), and lipid abnormalities (HDL, LDL, triglycerides)
|
Baseline, 3 months, 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Christine Burt Solorzano, MD, University of Virginia
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Neoplasms
- Endocrine System Diseases
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Diabetes Mellitus
- Hyperinsulinism
- Body Weight Changes
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Diabetes Mellitus, Type 2
- Polycystic Ovary Syndrome
- Insulin Resistance
- Body Weight
- Weight Gain
Other Study ID Numbers
Other Study ID Numbers
- 16132
- U54HD028934-18 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.